4'-Hydroxyphenyl carvedilol - CAS 142227-49-4
Not Intended for Therapeutic Use. For research use only.
Product Name:
4'-Hydroxyphenyl carvedilol
Catalog Number:
(R)-(+)-4'-HYDROXYPHENYL-CARVEDILOL;(S)-(-)-4'-HYDROXYPHENYL-CARVEDILOL;(R)-4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]ethoxy]-3-methoxyphenol;(R)-4-Hydroxycarvedilol;(R)-BM 140686;(R)-BM 14686;(S)-4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl
CAS Number:
4'-Hydroxyphenyl carvedilol, as a metabolite of Carvedilol it is a nonselective beta blocker/alpha-1 blocker.
Molecular Weight:
Molecular Formula:
Canonical SMILES:
Chemical Structure
CAS 142227-49-4 4'-Hydroxyphenyl carvedilol

Related Products

Bethanidine Sulfate
(CAS: 114-85-2)

This active molecular is a guanidinium antihypertensive agent through adrenergic neuron-blocking.

(CAS: 1253186-56-9)

This active molecular is a calcium release-activated calcium modulator (ORAI1) inhibitor. GSK-7975A inhibited toxin-induced activation of ORAI1 and/or activatio...

CAS 1146-98-1 Bromindione

(CAS: 1146-98-1)

Bromindione, an inandione derivative, could be used as an orally bioavaliable anticoagulant.

(CAS: 317846-22-3)

JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and ...

(CAS: 172618-05-2)

CP-100829, an indole derivative, could probably be useful in some biological studies.

SGD 1269
(CAS: 863971-19-1)

SGD 1269 is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases. It is a protective group-conjugated MMAF, ...

CAS 2447-54-3 Sanguinarine

(CAS: 2447-54-3)

Sanguinarine caused cell death in a dose dependent manner in all neuroblastoma cell lines except SK-N-BE(2) with rates of 18% in SH-SY5Y and 21% in Kelly human ...

(CAS: 1818885-28-7)

ARV-825, a BRD4 inhibitor, has extensive anti-AML activity and modulates tumor microenvironment and metabolism to overcome stromamediated drug resistance. DC50...

CAS 140678-14-4 Mangafodipir Trisodium

Mangafodipir Trisodium
(CAS: 140678-14-4)

The trisodium salt form of Mangafodipir that has been found to be a contrast agent through intravenously Mangafodipir Trisodium is a contrast agent delivered in...

CAS 34031-32-8 Auranofin

(CAS: 34031-32-8)

Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA, as an inhibitor of thioredoxin reductase (TrxR) (IC50 = 20 nM; Ki = 4 nM for the NADPH-reduced form of...

CAS 11027-63-7 Agnuside

(CAS: 11027-63-7)

Agnuside is an iridoid glycoside found in the herbs of Vitex agnus-castus, a plant native to the Mediterranean region. It is the ester of aucubin and p-hydroxyb...

CAS 33450-08-7 MK 436

MK 436
(CAS: 33450-08-7)

MK436 is an anti-protozoal drug has been found to be effective against Trypanosoma cruzi infections.

CAS 59721-29-8 Camostat Mesilate

Camostat Mesilate
(CAS: 59721-29-8)

Camostat (INN) or FOY-305 is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range o...

CAS 23327-57-3 Nefopam Hydrochloride

Nefopam Hydrochloride
(CAS: 23327-57-3)

Nefopam HCl is a centrally-acting but non-opioid analgesic drug by blocking voltage-gated sodium channel and inhibition of serotonin, dopamine and noradrenaline...

CAS 108437-28-1 Binfloxacin

(CAS: 108437-28-1)

Binfloxacin, a bio-active chemical compound, has antibiotic effect.

CAS 900510-03-4 PF-3274167

(CAS: 900510-03-4)

PF-3274167, also known as PF-03274167 or PF-327,4167, is a potent and selective, high-affinity nonpeptide oxytocin receptor antagonist.

CAS 183293-82-5 Gemcabene

(CAS: 183293-82-5)

Gemcabene is an orally available lipid-lowering small molecule designed to target known lipid metabolic pathways, as an adjunctive therapy to reduce LDL-C, hsCR...

CAS 27314-97-2 Tirapazamine

(CAS: 27314-97-2)

Tirapazamine is a benzotriazine di-N-oxide with potential antineoplastic activity. Tirapazamine is selectively activated by multiple reductases to form free rad...

Evogliptin hydrochloride
(CAS: 1246960-27-9)

CAS 56180-94-0 Acarbose

(CAS: 56180-94-0)

Acarbose is an inhibitor of intestinal alpha-glucosidase, used to treat type 2 diabetes mellitus.

Reference Reading

1.Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
Wang L1, Wang S2, Chen M1, Chen X1, Lin Y1, Hu X1, Huang X1, Li X1, Hu G1. Drug Dev Ind Pharm. 2015;41(10):1661-6. doi: 10.3109/03639045.2014.983930. Epub 2014 Nov 24.
The aim of this study was to investigate the effect of orally administered ketoconazole and voriconazole on the pharmacokinetics of carvedilol and its metabolites in rats. Fifteen healthy male Sprague-Dawley (SD) rats were randomly divided into three groups: A group (30 mg/kg ketoconazole), B group (30 mg/kg voriconazole) and C group (control group). A single dose of carvedilol was administered orally 30 min after administration of ketoconazole and voriconazole. Carvedilol and its metabolites plasma levels were measured by ultra-high performance liquid chromatography-mass spectrometry method (UPLC-MS/MS), and pharmacokinetic parameters were calculated by DAS 3.0 software. The co-administrated with ketoconazole could significantly increase the maximal plasma concentration (Cmax) and area under the curve (AUC) of carvedilol (p < 0.01). And the Cmax of its three metabolites 4'-hydroxyphenyl carvedilol (4'-HPC), 5'-hydroxyphenyl carvedilol (5'-HPC) and o-desmethyl carvedilol (o-DMC) decreased drastically by 39.
2.Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application.
Li J1, Wang L1, Wang S2, Chen M1, Gu E1, Hu G1, Ge R3. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 1;974:138-46. doi: 10.1016/j.jchromb.2014.10.037. Epub 2014 Nov 4.
A rapid-resolution ultra high-performance liquid chromatography-tandem mass spectrometry separation method (UPLC-MS/MS) was developed for the simultaneous determination of carvedilol, and its three metabolites: 4'-hydroxyphenyl-carvedilol, 5'-hydroxyphenyl-carvedilol, o-desmethyl-carvedilol. The effective UPLC-MS/MS separation of the examined compounds was applied on an Acquity BEH C18 column (2.1 mm × 5 0 mm, 1.7 μm particle size) column with a gradient mobile phase system. The analysis was performed in less than 6 min with a flow rate of 0.4 mL/min. The assay was validated over concentration ranges of 0.500-100 ng/mL for carvedilol and 0.0500-10.0 ng/mL for its three metabolites. Intra- and inter-assay precision values for replicate quality control samples were within 11.4% for all analytes during the assay validation. Mean quality control accuracy values were within ±11.5% of nominal values for all analytes. Assay recoveries were high (>91%) and internal standard normalized matrix effects were minimal.
3.A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl
Furlong MT1, He B, Mylott W, Zhao S, Mariannino T, Shen J, Stouffer B. J Pharm Biomed Anal. 2012 Nov;70:574-9. doi: 10.1016/j.jpba.2012.05.026. Epub 2012 May 30.
Carvedilol is widely prescribed for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction. A sensitive and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed and validated to enable reliable and efficient bioanalysis of the (R)- and (S)-enantiomers of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma. Following plasma extraction using supported liquid extraction (SLE) in a 96-well plate format, extracted samples were derivatized with 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate (GITC). Chromatographic separation was achieved by gradient elution on an ACQUITY UPLC HSS T3 analytical column. The impact of several potentially interfering isobaric metabolites on the quantification of the 4'-hydroxyphenyl metabolite (R)- and (S)-enantiomers was minimized by implementation of a combination of chromatographic and mass spectrometric techniques.
4.The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo.
Lin D1, Wang Z, Li J, Wang L, Wang S, Hu GX, Liu X. Pharmacology. 2016;97(1-2):31-7. doi: 10.1159/000441228. Epub 2015 Nov 17.
BACKGROUND: In light of the growing number of cancer survivors, the incidence of cardiovascular complications in these patients had also increased, while the effect of apatinib on the pharmacokinetic of cardioprotective drug (carvedilol) in rats or human is still unknown. The present work was to study the impact of apatinib on the metabolism of carvedilol both in vitro and vivo.